Abstract
The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Reviews on Recent Clinical Trials
Title:Gut Microbiota and Alcoholic Liver Disease
Volume: 11 Issue: 3
Author(s): Emidio Scarpellini, Mariana Forlino, Marinella Lupo, Carlo Rasetti, Giammarco Fava, Ludovico Abenavoli and Adriano De Santis
Affiliation:
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Abstract: The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Export Options
About this article
Cite this article as:
Scarpellini Emidio, Forlino Mariana, Lupo Marinella, Rasetti Carlo, Fava Giammarco, Abenavoli Ludovico and De Santis Adriano, Gut Microbiota and Alcoholic Liver Disease, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160810100538
DOI https://dx.doi.org/10.2174/1574887111666160810100538 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of TRP Channels in Allergic Inflammation and its Clinical Relevance
Current Medicinal Chemistry Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology
Current Molecular Medicine Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Current Gene Therapy Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential of Plant Mucilages in Pharmaceuticals and Therapy
Current Drug Delivery Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Cellular and Humoral Responses following Minimally Invasive Surgery: Role of Reactive Oxygen Species
Current Metabolomics Editorial (Thematic Issue: The Crosstalk between Non-Pharmaceutical and Pharmaceutical Approaches to Prevention and Treatment of Chronic Diseases: Current Concepts and Perspectives)
Current Pharmaceutical Design Use of Trastuzumab for Breast Cancer: The Role of Age
Current Pharmaceutical Design PPARs in Diseases: Control Mechanisms of Inflammation
Current Medicinal Chemistry Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology